The ethics and practicalities of controlled human infection with SARS-CoV-2 have been widely discussed. Potential risks are clear. The case in favour hinges upon whether these risks can be mitigated to an acceptable, very low, level and whether the studies will provide substantial benefits that could not readily be obtained by other means. Here, we discuss the immunological considerations relating to each side of this balance. In this Comment article, Sandy Douglas and Adrian Hill discuss the immunological considerations associated with a risk–benefit analysis for controlled human infection models of SARS-CoV-2.

中文翻译：

---

SARS-CoV-2人类挑战研究的免疫学考虑

人们广泛讨论了SARS-CoV-2控制人类感染的伦理学和实用性。潜在风险显而易见。有利的情况取决于这些风险是否可以降低到可接受的，非常低的水平，以及这些研究是否将提供其他方式无法轻易获得的实质性收益。在这里，我们讨论与平衡的每一侧有关的免疫学考虑。在这篇评论文章中，桑迪·道格拉斯（Sandy Douglas）和阿德里安·希尔（Adrian Hill）讨论了与SARS-CoV-2受控人类感染模型的风险效益分析相关的免疫学考虑。